Retinoid Pathways In The Developing Fetal Lung Disrupted By Maternal Smoking

Retinoid Pathways In The Developing Fetal Lung Disrupted By Maternal Smoking

Main Category: Pregnancy / Obstetrics
Also Included In: Respiratory / Asthma;  Pediatrics / Children's Health;  Smoking / Quit Smoking
Article Date: 03 Jun 2012 - 0:00 PDT

email to a friend   printer friendly   opinions   <!-- rate article
Patient / Public:

Healthcare Prof:

Maternal smoking can lead to lung disease in babies, including asthma. New research published in BioMed Central's open access journal Respiratory Research shows that maternal smoking-related defects within the alveoli inside the lungs of offspring are associated with a disruption in retinoic acid signaling.

It is known that the effects of smoking on the developing lung have long term consequences for the child's health. Children of mothers who smoke have an increased risk of asthma and lung infections and have a more rapid decline of lung function if they begin to smoke as adults. In order to understand the mechanism behind this, researchers from the Brigham and Women's Hospital looked at the effect of maternal smoking on retinoic acid signaling in mice. Retinoic acid (RA) is produced in the body from vitamin A and is known to be involved in alveolar development as well as lung maintenance throughout life.

Maternal smoking affected the number and birth weight of their pups. It also affected the development of the pups' lungs (measured by approximate size of the gas exchange elements of the lungs) and disrupted RA signaling in their lungs. Reduction of RA signaling was also seen in lung cells treated with cigarette smoke in the lab.

Dr Kathleen Haley, who led the research, explained, "The pups were protected from breathing smoke themselves but were still affected by 'second hand' smoke before birth and through their mother's milk. Smoking affected the regulation of genes, controlled by RA, necessary for lung development, including surfactant apoprotein B. It is known that complete loss of surfactant apoprotein B is linked to severe respiratory failure in infants and down regulation of this, and other genes regulated by RA, can have potentially serious consequences."

The decreases in RA signaling and in the expression of RA controlled genes were most pronounced during the 3-5 days after birth when the lungs are undergoing rapid development. In humans this development stage occurs before birth when the developing fetus receives 'second hand' smoke via the umbilical cord so it seems very likely that the same damaging effects of cigarette smoke on RA signaling are present in humans too.

• Additional
• References
• Citations

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

---

APA

---

Please note: If no author information is provided, the source is cited instead.

---

Add Your Opinion On This Article

'Retinoid Pathways In The Developing Fetal Lung Disrupted By Maternal Smoking'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.

back to top | home | privacy policy

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.